Arcutis Biotherapeutics (ARQT) Preferred Stock Liabilities (2019)

Arcutis Biotherapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $166.5 million for Q4 2019.

• In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $166.5 million; the TTM figure through Dec 2019 stood at $166.5 million (changed N/A YoY), while the FY2019 annual figure was $166.5 million, up 130.43% from the prior year.
• Preferred Stock Liabilities for Q4 2019 stood at $166.5 million, up from $72.3 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $166.5 million in Q4 2019, with the low at $72.3 million in Q1 2019.